These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 29427770)

  • 1. Impact of SLC22A1 and CYP3A5 genotypes on imatinib response in chronic myeloid leukemia: A systematic review and meta-analysis.
    Cargnin S; Ravegnini G; Soverini S; Angelini S; Terrazzino S
    Pharmacol Res; 2018 May; 131():244-254. PubMed ID: 29427770
    [TBL] [Abstract][Full Text] [Related]  

  • 2. OCT1 genetic variants are associated with long term outcomes in imatinib treated chronic myeloid leukemia patients.
    Koren-Michowitz M; Buzaglo Z; Ribakovsky E; Schwarz M; Pessach I; Shimoni A; Beider K; Amariglio N; le Coutre P; Nagler A
    Eur J Haematol; 2014 Apr; 92(4):283-8. PubMed ID: 24215657
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Influence of MDR1 and CYP3A5 genetic polymorphisms on trough levels and therapeutic response of imatinib in newly diagnosed patients with chronic myeloid leukemia.
    Harivenkatesh N; Kumar L; Bakhshi S; Sharma A; Kabra M; Velpandian T; Gogia A; Shastri SS; Biswas NR; Gupta YK
    Pharmacol Res; 2017 Jun; 120():138-145. PubMed ID: 28330783
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Influence of genetic polymorphisms on imatinib concentration and therapeutic response in patients with chronic-phase chronic myeloid leukemia.
    Cheng F; Cui Z; Li Q; Chen S; Li W; Zhang Y
    Int Immunopharmacol; 2024 May; 133():112090. PubMed ID: 38640718
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genetic variations of hOCT1 gene and CYP3A4/A5 genes and their association with imatinib response in Chronic Myeloid Leukemia.
    Vaidya S; Ghosh K; Shanmukhaiah C; Vundinti BR
    Eur J Pharmacol; 2015 Oct; 765():124-30. PubMed ID: 26300393
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SLC22A1-ABCB1 haplotype profiles predict imatinib pharmacokinetics in Asian patients with chronic myeloid leukemia.
    Singh O; Chan JY; Lin K; Heng CC; Chowbay B
    PLoS One; 2012; 7(12):e51771. PubMed ID: 23272163
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Do SLCO1B3 (T334G) and CYP3A5*3 polymorphisms affect response in Egyptian chronic myeloid leukemia patients receiving imatinib therapy?
    Bedewy AM; El-Maghraby SM
    Hematology; 2013 Jul; 18(4):211-6. PubMed ID: 23394475
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical relevance of a pharmacogenetic approach using multiple candidate genes to predict response and resistance to imatinib therapy in chronic myeloid leukemia.
    Kim DH; Sriharsha L; Xu W; Kamel-Reid S; Liu X; Siminovitch K; Messner HA; Lipton JH
    Clin Cancer Res; 2009 Jul; 15(14):4750-8. PubMed ID: 19584153
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Trough concentration and ABCG2 polymorphism are better to predict imatinib response in chronic myeloid leukemia: a meta-analysis.
    Jiang ZP; Zhao XL; Takahashi N; Angelini S; Dubashi B; Sun L; Xu P
    Pharmacogenomics; 2017 Jan; 18(1):35-56. PubMed ID: 27991849
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Do polymorphisms in MDR1 and CYP3A5 genes influence the risk of cytogenetic relapse in patients with chronic myeloid leukemia on imatinib therapy?
    Harivenkatesh N; Kumar L; Bakhshi S; Sharma A; Kabra M; Velpandian T; Gogia A; Shastri SS; Gupta YK
    Leuk Lymphoma; 2017 Sep; 58(9):1-9. PubMed ID: 28367681
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Influence of CYP3A5*3 and ABCB1 C3435T on clinical outcomes and trough plasma concentrations of imatinib in Nigerians with chronic myeloid leukaemia.
    Adeagbo BA; Bolaji OO; Olugbade TA; Durosinmi MA; Bolarinwa RA; Masimirembwa C
    J Clin Pharm Ther; 2016 Oct; 41(5):546-51. PubMed ID: 27426203
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reduced ABCG2 and increased SLC22A1 mRNA expression are associated with imatinib response in chronic myeloid leukemia.
    de Lima LT; Vivona D; Bueno CT; Hirata RD; Hirata MH; Luchessi AD; de Castro FA; de Lourdes F Chauffaille M; Zanichelli MA; Chiattone CS; Hungria VT; Guerra-Shinohara EM
    Med Oncol; 2014 Mar; 31(3):851. PubMed ID: 24469953
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genetic variations in influx transporter gene
    Makhtar SM; Husin A; Baba AA; Ankathil R
    J Genet; 2018 Sep; 97(4):835-842. PubMed ID: 30262695
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of Trough Concentration and Solute Carrier Polymorphisms on Imatinib Efficacy in Chinese Patients with Chronic Myeloid Leukemia.
    Wang Q; Jiang ZP; Zeng J; Zhu Y; Cai HL; Xiang DX; He Q; Shi XL; Zhong AN; Zhao XL; Xu P
    J Pharm Pharm Sci; 2020; 23(1):1-9. PubMed ID: 32027818
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association of SLC22A1,SLCO1B3 Drug Transporter Polymorphisms and Smoking with Disease Risk and Cytogenetic Response to Imatinib in Patients with Chronic Myeloid Leukemia.
    Mohammadi F; Rostami G; Assad D; Shafiei M; Hamid M; Jalaeikhoo H
    Lab Med; 2021 Nov; 52(6):584-596. PubMed ID: 34128532
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association of
    Asadov C; Karimova N; Hasanova A; Bayramov B; Shirinova A; Alimirzoyeva Z
    Indian J Med Res; 2023 Aug; 158(2):151-160. PubMed ID: 37706370
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association of ABCB1, ABCG2 drug transporter polymorphisms and smoking with disease risk and cytogenetic response to imatinib in chronic myeloid leukemia patients.
    Mohammadi F; Rostami G; Hamid M; Shafiei M; Azizi M; Bahmani H
    Leuk Res; 2023 Mar; 126():107021. PubMed ID: 36696828
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association of genetic polymorphisms in the influx transporter SLCO1B3 and the efflux transporter ABCB1 with imatinib pharmacokinetics in patients with chronic myeloid leukemia.
    Yamakawa Y; Hamada A; Nakashima R; Yuki M; Hirayama C; Kawaguchi T; Saito H
    Ther Drug Monit; 2011 Apr; 33(2):244-50. PubMed ID: 21311410
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relationship between SLCO1B3 and ABCA3 polymorphisms and imatinib response in chronic myeloid leukemia patients.
    de Lima LT; Bueno CT; Vivona D; Hirata RD; Hirata MH; Hungria VT; Chiattone CS; Zanichelli MA; Chauffaille Mde L; Guerra-Shinohara EM
    Hematology; 2015 Apr; 20(3):137-42. PubMed ID: 25056761
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Influence of enzyme and transporter polymorphisms on trough imatinib concentration and clinical response in chronic myeloid leukemia patients.
    Seong SJ; Lim M; Sohn SK; Moon JH; Oh SJ; Kim BS; Ryoo HM; Chung JS; Joo YD; Bang SM; Jung CW; Kim DH; Park SY; Yoon SS; Kim I; Lee HG; Won JH; Min YH; Cheong JW; Park JS; Eom KS; Hyun MS; Kim MK; Kim H; Park MR; Park J; Kim CS; Kim HJ; Kim YK; Park EK; Zang DY; Jo DY; Lee HW; Yoon YR
    Ann Oncol; 2013 Mar; 24(3):756-60. PubMed ID: 23117072
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.